Author/Authors :
Payandeh، Mehrdad نويسنده Dept. of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran , , Khodarahmi، Reza نويسنده Department of Pharmacognosy and Biotechnology, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran Khodarahmi, Reza , Sadeghi، Masoud نويسنده Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran Sadeghi, Masoud , Sadeghi، Edris نويسنده Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran ,
Abstract :
Acute Myelogenous Leukemia (AML) is an aggressive hematologic malignancy that cause by abnormal proliferation and accumulation of hematopoietic progenitor cells. A 37-year-old woman referred to oncologic clinic with a self-detected mass and pain in her left breast. The stage of tumor was ???A. She was treated with the combination of anthracycline and cyclophosphamide for four courses, followed by four courses of paclitaxel with trastuzumab for one year. After 18 months of the first treatment for breast cancer, her bone marrow biopsy was compatible with AML-M2.
Here, we are reporting a young woman case with breast cancer that developed AML malignancy during short interval of therapy.
